The Pune-based Serum Institute of India (SII), a global frontrunner seeking to develop a safe and effective COVID vaccine, has registered its second and third phase trials of the Oxford-AstraZeneca Coronavirus (Covid-19) vaccine candidate – ‘Covishield’- with the Clinical Trials Registry of India (CTRI). The trails will be conducted on 1,600 healthy participants across India. […]